Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, ≥18 years of age at Screening.~2. Confirmed infection with SARS-CoV-2.~3. High risk of COVID-19 disease progression, defined as:~   1. 18-69 years of age with lymphopenia AND 1 additional risk factor (described below)~  2. 18-69 years of age without lymphopenia AND 2 risk factors (described below)~  3. ≥70 years of age with lymphopenia OR 1 other risk factor (described below)~   Risk Factors:~  * Documented history of coronary artery disease~  * Heart failure (New York Heart Association Class 3 or 4)~  * Chronic lung disease (eg, asthma or chronic obstructive pulmonary disease) requiring treatment~  * Documented history of stroke~  * Diabetes mellitus, requiring at least 1 prescription medicine for management~  * Documented chronic kidney disease with an estimated glomerular filtration rate \<30 mL/min, not on dialysis~  * Obesity (Class 2 or 3; body mass index \>34.9 kg/m2)~  * On immunosuppressive therapy~  * Oxygen saturation between 90 and 95% with or without supplemental oxygen~4. Admitted to a hospital for observation and/or treatment (controlled facility may include an emergency room, urgent care facility, temporary/modular hospital, infusion center, clinical research unit, etc).~5. If female, must be postmenopausal, surgically sterile, or if of childbearing potential, must be practicing 2 effective methods of birth control during the study and through 30 days after completion of the study.~6. For females of childbearing potential, a urine pregnancy test must be negative at the Screening Visit.~7. If male, must be surgically sterile or willing to practice 2 effective methods of birth control during the study and through 30 days after completion of the study.~8. Must be willing and able to give informed consent and comply with all study procedures.~Exclusion Criteria:~1. Anticipated need for ICU care and/or ventilatory support (invasive or noninvasive) within 24 hours.~2. Evidence of acute cardiac injury, as determined by the Investigator at the time of Screening. This may be based upon clinical signs and symptoms, ECG findings, or elevated troponin I levels.~3. Evidence of acute kidney injury not due to pre-renal azotemia or urinary tract obstruction at the time of Screening.~4. Oxygen saturation \<90% on supplemental oxygen with a nasal cannula, including high-flow oxygen at the time of Screening.~5. Requires non-invasive ventilation at the time of Screening.~6. Requires dialysis at the time of Screening.~7. Has received or is receiving anti-IL-6 therapies (eg, Tocilizumab, Sarilumab, Siltuximab, etc) for the treatment of COVID-19; subjects receiving anti-IL-6 therapies for underlying medical conditions unrelated to COVID-19 are not excluded from eligibility.~8. Pregnant or lactating.~9. History of photosensitivity or active skin disease that, in the opinion of the Investigator, could be worsened by RBT-9.~10. Known hypersensitivity or previous anaphylaxis to RBT-9 (stannous protoporphyrin) or any tin-based product.~11. Treatment with an investigational drug or participation in an interventional trial within 30 days prior to the first dose of study drug.~12. Inability to comply with the requirements of the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBT-9 (90 mg) (Type: EXPERIMENTAL): RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).